EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Impact of Multigene Panel Testing in High‐Risk Uveal Melanoma Patients

Lindsey Byrne iD, Isabella Gray, Kaylee Ramsey, Joseph McElroy, Emma Schreiner, Jenna Wolfe, Olivia B Taylor iD, Frederick Davidorf, Colleen M Cebulla iD, Mohamed H Abdel-Rahman iD

Pigment Cell & Melanoma Research · 2026-07 · 39 (4)

DOI: 10.1111/pcmr.70108 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pigment Cell & Melanoma Research, online erschienen am 07.07.2026. Verfasst von Lindsey Byrne und 9 weiteren Autor:innen. Beteiligte Einrichtung: The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Columbus, Ohio, USA. Hauptthemen laut MEDLINE: Uveal Neoplasms, Melanoma, Genetic Testing, Genetic Predisposition to Disease. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: U.S. Department of Defense, NCATS NIH HHS, Ohio Lions Eye Research Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Germline genetic testing is increasingly incorporated into the care of patients with uveal melanoma, yet optimal testing strategies remain unclear. This study aimed to evaluate the outcome of germline clinical genetic testing in uveal melanoma (UM) patients who met the National Comprehensive Cancer Network (NCCN) guidelines for genetic testing. A retrospective chart review was conducted on UM patients seen in The Ohio State University Cancer Genetics Clinic between 5/1/2021 and 9/19/2025. Seventy individuals underwent clinical genetic testing, primarily via large multigene panels. Ten UM patients, including two related individuals, had pathogenic or likely pathogenic (P/LP) variants in known cancer genes ( BAP1, BRCA1, BRCA2, MBD4, MUTYH, POT1, XRCC2 ). Among unrelated individuals, the positive rate was 13% (8/69). Excluding carrier genes, the rate was 10.1% (7/69). Eight patients would have been missed if only tested for BAP1 per American Society of Clinical Oncology (ASCO) 2024 recommendations. There was no association between tumor size, stage, and germline P/LP variants. In summary, NCCN guidelines are useful in the prioritization of UM patients for genetic testing. Additionally, these findings support genetic counseling for multigene panel testing in high‐risk uveal melanoma patients. Further studies of the impact of germline variants on UM disease outcome are warranted.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Uveal NeoplasmsMelanomaGenetic TestingGenetic Predisposition to DiseaseHumansUveal MelanomaFemaleMaleMiddle AgedAgedAdultGerm-Line MutationRisk Factors

Stichwörter der Autor:innen

cancer genesgenetic counselinggenetic testinggermlineretrospectiveuveal melanoma

Autor:innen und Institutionen

  • The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Columbus, Ohio, USA.
  • Division of Human Genetics, Department of Internal Medicine, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA.
  • Department of Ophthalmology and Visual Sciences, Havener Eye Institute, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA.
  • Center for Biostatistics, Department of Biomedical Informatics, College of Medicine, The Ohio State University, Columbus, Ohio, USA.

ORCID-Profile: Lindsey Byrne, Olivia B Taylor, Colleen M Cebulla, Mohamed H Abdel-Rahman

Förderung

  • U.S. Department of Defense
  • NCATS NIH HHS
  • Ohio Lions Eye Research Foundation
  • Research to Prevent Blindness
  • Patti Blow Research Fund in Ophthalmology
  • NCI NIH HHS
  • NEI NIH HHS
  • National Cancer Institute

Zitieren

APA

Byrne, L., Gray, I., Ramsey, K., McElroy, J., Schreiner, E., Wolfe, J., Taylor, O. B., Davidorf, F., Cebulla, C. M., & Abdel-Rahman, M. H. (2026). Impact of Multigene Panel Testing in High‐Risk Uveal Melanoma Patients. Pigment Cell & Melanoma Research, 39(4). https://doi.org/10.1111/pcmr.70108

Vancouver

Byrne L, Gray I, Ramsey K, McElroy J, Schreiner E, Wolfe J, et al. Impact of Multigene Panel Testing in High‐Risk Uveal Melanoma Patients. Pigment Cell & Melanoma Research. 2026;39(4). doi:10.1111/pcmr.70108

BibTeX
@article{Byrne2026,
  author = {Byrne, Lindsey and Gray, Isabella and Ramsey, Kaylee and McElroy, Joseph and Schreiner, Emma and Wolfe, Jenna and Taylor, Olivia B and Davidorf, Frederick and Cebulla, Colleen M and Abdel-Rahman, Mohamed H},
  title = {Impact of Multigene Panel Testing in High‐Risk Uveal Melanoma Patients},
  journal = {Pigment Cell & Melanoma Research},
  year = {2026},
  volume = {39},
  number = {4},
  doi = {10.1111/pcmr.70108}
}
Kostenlos starten →